Advances in the treatment of prostate cancer with radiotherapy.

[1]  Jurgen J Fütterer,et al.  Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. , 2014, AJR. American journal of roentgenology.

[2]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[4]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[5]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[6]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[7]  Y. Lotan,et al.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Hahn,et al.  Reference pricing with evidence development: a way forward for proton therapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Bortfeld.  IMRT: a review and preview , 2006, Physics in medicine and biology.

[10]  M. Fu,et al.  Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer? , 2013, Seminars in oncology.

[11]  C. Tan,et al.  Diffusion-weighted MRI of adult male pelvic cancers. , 2012, Clinical radiology.

[12]  Lidia Strigari,et al.  A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. , 2010, International journal of radiation oncology, biology, physics.

[13]  Roy S Herbst,et al.  Mode of action of docetaxel - a basis for combination with novel anticancer agents. , 2003, Cancer treatment reviews.

[14]  Ronald C. Chen,et al.  Phase I study of concurrent weekly docetaxel, high‐dose intensity‐modulated radiation therapy (IMRT) and androgen‐deprivation therapy (ADT) for high‐risk prostate cancer , 2012, BJU international.

[15]  A. P. Reuvers,et al.  Studies on the Radiosensitizing Effect of Oxygen in Chinese Hamster Cells , 1974 .

[16]  P. Lavori,et al.  Analysis of randomized controlled trials. , 2002, Epidemiologic reviews.

[17]  C. Magi-Galluzzi,et al.  Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer. , 2012 .

[18]  S. Formenti.  Immunological aspects of local radiotherapy: clinical relevance. , 2010, Discovery medicine.

[19]  P. Choyke,et al.  11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation , 2012, The Journal of Nuclear Medicine.

[20]  Alexandra L Hanlon,et al.  Radiation dose and late failures in prostate cancer. , 2007, International journal of radiation oncology, biology, physics.

[21]  J. Hendry,et al.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. , 2012, International journal of radiation oncology, biology, physics.

[22]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[23]  Matthew Sydes,et al.  Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. , 2008, The Lancet. Oncology.

[24]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[25]  Jay L. Friedland,et al.  Stereotactic Body Radiotherapy: An Emerging Treatment Approach for Localized Prostate Cancer , 2009, Technology in cancer research & treatment.

[26]  D. Kuban,et al.  Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer using Hypofractionation , 2010 .

[27]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[28]  R. DiPaola,et al.  Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Wilson.  Radiological use of fast protons. , 1946, Radiology.

[30]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[31]  Pamela Catton,et al.  Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[32]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[33]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[34]  J. Bussink,et al.  Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. , 2008, The Lancet. Oncology.

[35]  A. Dicker,et al.  mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer , 2011, Endocrine-related cancer.

[36]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[37]  S. Formenti,et al.  Regulation of Protein Synthesis by Ionizing Radiation , 2009, Molecular and Cellular Biology.

[38]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[39]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[40]  A. Fiorentino,et al.  In regard to Miralbell et al. Re: Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta=1.4 (0.9-2.2) Gy. , 2013, International journal of radiation oncology, biology, physics.

[41]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[42]  R. Stoyanova,et al.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  N. Jiang,et al.  Who benefits from hypofractionated radiation therapy for clinically localized prostate cancer: evidence from meta-analysis , 2014, Tumor Biology.

[44]  Go Kimura,et al.  Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT , 2012, Annals of Nuclear Medicine.

[45]  F. McCormick,et al.  Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. , 1998, Science.

[46]  Zuofeng Li,et al.  Rectal toxicity after proton therapy for prostate cancer: an analysis of outcomes of prospective studies conducted at the university of Florida Proton Therapy Institute. , 2015, International journal of radiation oncology, biology, physics.

[47]  C. Logothetis,et al.  Novel therapies for metastatic castrate-resistant prostate cancer. , 2011, Journal of the National Cancer Institute.

[48]  M. Dewhirst,et al.  HIF-1 and tumour radiosensitivity , 2006, British Journal of Cancer.

[49]  G. Viani,et al.  Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. , 2009, International journal of radiation oncology, biology, physics.

[50]  A Clinical Review on Extreme Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer Using Nonrobotic Linear Accelerators , 2014, Cancer investigation.

[51]  Josephine Kang,et al.  Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year Study , 2014, Front. Oncol..

[52]  P. Choyke,et al.  Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[53]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[54]  C. Ménard,et al.  Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer , 2012, Clinical Cancer Research.

[55]  Zuofeng Li,et al.  Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. , 2014, International journal of radiation oncology, biology, physics.

[56]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[57]  M. Bolla,et al.  Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[58]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[59]  W. Sellers,et al.  Akt-regulated pathways in prostate cancer , 2005, Oncogene.

[60]  H. Willers,et al.  Introduction to clinical radiation biology. , 2006, Hematology/oncology clinics of North America.

[61]  K. W. Kim,et al.  Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. , 2006, Cancer research.

[62]  John T. Wei,et al.  RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. , 2014, The Lancet. Oncology.

[63]  J. Fowler,et al.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. , 2007, International journal of radiation oncology, biology, physics.

[64]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[65]  M. Parmar,et al.  Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. , 2014, The Lancet. Oncology.

[66]  Jarad Martin,et al.  Defining a dose–response relationship for prostate external beam radiotherapy , 2013, Journal of medical imaging and radiation oncology.

[67]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.